<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03463512</url>
  </required_header>
  <id_info>
    <org_study_id>RACE3003</org_study_id>
    <nct_id>NCT03463512</nct_id>
  </id_info>
  <brief_title>Controlled Study to Evaluate the Efficacy and Safety of Racecadotril in Infants, Children and Adolescents With Acute Diarrhea</brief_title>
  <official_title>Multicenter, Open-label, Controlled, Randomized Clinical Study to Evaluate the Efficacy and Safety of Racecadotril in Infants, Children and Adolescents With Acute Diarrhea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, open-label, controlled, randomized clinical study to evaluate the efficacy and
      safety of Racecadotril in infants, children and adolescents with acute diarrhea
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 29, 2018</start_date>
  <completion_date type="Actual">September 10, 2018</completion_date>
  <primary_completion_date type="Actual">September 10, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Diarrhea (Hours) Between the Start of Treatment Until Last Diarrheal/Watery Stool Before Recovery or End of Study Treatment (Treatment Duration Maximal 5 Days)</measure>
    <time_frame>5 days</time_frame>
    <description>Duration of diarrhea is defined by date and time of the evacuation of the final diarrheal stool derived from the daily diary.
Log-rank test was performed with a p-value &lt; 0.0001</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Recovered Subjects Per Treatment Group.</measure>
    <time_frame>5 days</time_frame>
    <description>Number of recovered subjects per treatment group. Recovery is defined as the evacuation of the first of two consecutive normal stools or no stool within 12 h within treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Recovered Subjects as Defined by Global Physician Assessment of Success at the End of Treatment</measure>
    <time_frame>5 days</time_frame>
    <description>Globabl physician assessment used 6 scores with a score of 1 or 2 being regarded as treatment success</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Diarrhea</condition>
  <arm_group>
    <arm_group_label>Racecadotril plus standard treatment oral rehydration solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ORS (standard treatment)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Racecadotril plus ORS</intervention_name>
    <description>Racecadotril plus ORS</description>
    <arm_group_label>Racecadotril plus standard treatment oral rehydration solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORS</intervention_name>
    <description>ORS</description>
    <arm_group_label>ORS (standard treatment)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent from one of the parent(s)/caregiver(s) or subject informed
             assent

          -  Children and adolescents, both genders, age from 3 months to &lt; 18 years of age

          -  Confirmed diagnosis of acute diarrhea (defined as the passage of three or more
             unformed or liquid stools within the last 24 hours and lasting for less than three
             days)

          -  Females of child-bearing potential should agree to continue using a medically
             acceptable method of birth control throughout the study and for 30 days immediately
             after the last dose of study drug. Medically acceptable methods of birth control
             include bilateral tubal ligation or the use of either a contraceptive implant, a
             contraceptive injection, an intrauterine device, or an oral contraceptive taken within
             the past three months where the subject agrees to continue using during the study or
             to adopt another birth control method, or a double-barrier method which consists of a
             combination of any two of the following: diaphragm, cervical cap, condom, or
             spermicide

        Exclusion Criteria:

          -  Known allergy to Racecadotril or any of its ingredients

          -  Subjects suffering from renal or hepatic impairment

          -  Subjects who need treatment for diarrhea other than ORS alone

          -  Subjects with fever &gt; 39 degrees Celsius

          -  Subjects with bloody and/or purulent stools

          -  Subjects suffering from antibiotic-associated diarrhea, chronic diarrhea or iatrogenic
             diarrhea

          -  Subjects with alternating bouts of diarrhea and constipation

          -  Diarrhea due to exacerbation of chronic gastrointestinal diseases such as irritable
             bowel syndrome, inflammatory bowel disease or pancreatic exocrine insufficiency

          -  Cystic fibrosis or coeliac disease

          -  Subjects suffering from prolonged or uncontrolled vomiting

          -  Subjects with rare hereditary problems of fructose or galactose intolerance, Lapp
             lactase deficiency, glucose-galactose malabsorption syndrome or sucrase isomaltase
             insufficiency or primary or secondary lactase insufficiency

          -  Subjects having received antibiotic treatment at any time within 30 days prior to
             inclusion into the study

          -  Subjects having received antidiarrheal drugs 48 hours prior to inclusion into the
             study

          -  Subjects with severe dehydration required for intravenous/parenteral rehydration

          -  Subjects who have reported angioedema with angiotensin converting enzyme inhibitors
             (such as captopril, enalapril, lisinopril, perindopril, ramipril)

          -  Subjects with combined diseases or medical situations that would prevent to be
             enrolled depending in the judgment of the investigator

          -  Intake of experimental drug within 30 days prior to study start

          -  Subjects with contraindications to ORS or for whom warnings/precautions of ORS apply

          -  Adolescents (â‰¥ 60 kg) not able to swallow capsules

          -  Pregnancy and lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Saint Petersburg State Budgetary Healthcare Institution &quot;Municipal Outpatient Children Unit #45&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 5, 2018</study_first_submitted>
  <study_first_submitted_qc>March 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2018</study_first_posted>
  <results_first_submitted>August 13, 2019</results_first_submitted>
  <results_first_submitted_qc>October 22, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 23, 2019</results_first_posted>
  <last_update_submitted>October 22, 2019</last_update_submitted>
  <last_update_submitted_qc>October 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Racecadotril</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 30, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT03463512/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT03463512/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Racecadotril Plus Standard Treatment Oral Rehydration Solution</title>
          <description>Racecadotril plus ORS: Racecadotril plus ORS</description>
        </group>
        <group group_id="P2">
          <title>ORS (Standard Treatment)</title>
          <description>ORS: ORS</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Racecadotril Plus Standard Treatment Oral Rehydration Solution</title>
          <description>Racecadotril plus ORS: Racecadotril plus ORS</description>
        </group>
        <group group_id="B2">
          <title>ORS (Standard Treatment)</title>
          <description>ORS: ORS</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="62"/>
            <count group_id="B2" value="62"/>
            <count group_id="B3" value="124"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.2" spread="4.5"/>
                    <measurement group_id="B2" value="6.8" spread="4.6"/>
                    <measurement group_id="B3" value="6.5" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Duration of Diarrhea (Hours) Between the Start of Treatment Until Last Diarrheal/Watery Stool Before Recovery or End of Study Treatment (Treatment Duration Maximal 5 Days)</title>
        <description>Duration of diarrhea is defined by date and time of the evacuation of the final diarrheal stool derived from the daily diary.
Log-rank test was performed with a p-value &lt; 0.0001</description>
        <time_frame>5 days</time_frame>
        <population>full analysis sample</population>
        <group_list>
          <group group_id="O1">
            <title>Racecadotril Plus Standard Treatment Oral Rehydration Solution</title>
            <description>Racecadotril plus ORS: Racecadotril plus ORS</description>
          </group>
          <group group_id="O2">
            <title>ORS (Standard Treatment)</title>
            <description>ORS: ORS</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Diarrhea (Hours) Between the Start of Treatment Until Last Diarrheal/Watery Stool Before Recovery or End of Study Treatment (Treatment Duration Maximal 5 Days)</title>
          <description>Duration of diarrhea is defined by date and time of the evacuation of the final diarrheal stool derived from the daily diary.
Log-rank test was performed with a p-value &lt; 0.0001</description>
          <population>full analysis sample</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" spread="2.2"/>
                    <measurement group_id="O2" value="43.2" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Recovered Subjects Per Treatment Group.</title>
        <description>Number of recovered subjects per treatment group. Recovery is defined as the evacuation of the first of two consecutive normal stools or no stool within 12 h within treatment period</description>
        <time_frame>5 days</time_frame>
        <population>full analysis sample</population>
        <group_list>
          <group group_id="O1">
            <title>Racecadotril Plus Standard Treatment Oral Rehydration Solution</title>
            <description>Racecadotril plus ORS: Racecadotril plus ORS</description>
          </group>
          <group group_id="O2">
            <title>ORS (Standard Treatment)</title>
            <description>ORS: ORS</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Recovered Subjects Per Treatment Group.</title>
          <description>Number of recovered subjects per treatment group. Recovery is defined as the evacuation of the first of two consecutive normal stools or no stool within 12 h within treatment period</description>
          <population>full analysis sample</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Recovered Subjects as Defined by Global Physician Assessment of Success at the End of Treatment</title>
        <description>Globabl physician assessment used 6 scores with a score of 1 or 2 being regarded as treatment success</description>
        <time_frame>5 days</time_frame>
        <population>full analysis sample</population>
        <group_list>
          <group group_id="O1">
            <title>Racecadotril Plus Standard Treatment Oral Rehydration Solution</title>
            <description>Racecadotril plus ORS: Racecadotril plus ORS</description>
          </group>
          <group group_id="O2">
            <title>ORS (Standard Treatment)</title>
            <description>ORS: ORS</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Recovered Subjects as Defined by Global Physician Assessment of Success at the End of Treatment</title>
          <description>Globabl physician assessment used 6 scores with a score of 1 or 2 being regarded as treatment success</description>
          <population>full analysis sample</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 days + 1 gap day</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Racecadotril Plus Standard Treatment Oral Rehydration Solution</title>
          <description>Racecadotril plus ORS: Racecadotril plus ORS</description>
        </group>
        <group group_id="E2">
          <title>ORS (Standard Treatment)</title>
          <description>ORS: ORS</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Suntje Sander</name_or_title>
      <organization>Abbott</organization>
      <phone>+495116750 ext 3254</phone>
      <email>suntje.sander@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

